• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FIGO 2009 IB1 期宫颈癌患者行根治性子宫切除术,不辅以辅助放疗,无论 Sedlis 标准是否阳性。

Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.

机构信息

Division of Gynaecological Oncology, Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.

Department of Radiation-Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.

出版信息

Gynecol Oncol. 2021 Sep;162(3):539-545. doi: 10.1016/j.ygyno.2021.06.026. Epub 2021 Jul 10.

DOI:10.1016/j.ygyno.2021.06.026
PMID:34253389
Abstract

INTRODUCTION

Lymphovascular space invasion (LVSI), deep (>1/3) stromal invasion (DSI) and large tumor size (>4 cm) have been identified as predictors for intermediate risk for recurrence according to Sedlis (at least two of the prior risk factors) in FIGO stage I cervical cancer. Adjuvant radiotherapy (RT) has been advocated in these patients(1,2), but remains controversial.

METHOD

All consecutive patients (1997-2017) with cervical cancer FIGO (2009) stage IB1 (≤4 cm) were included. Primary aim was to analyze the recurrence rate. Secondary aim was to identify the risk factors for disease recurrence and survival.

RESULTS

One-hundred-and-eighty-two patients were included in this retrospective study. Median follow-up was 13 years (range 8-17). Postoperatively, 21 patients received adjuvant therapy due to presence of positive lymph nodes, positive section margins or if a simple hysterectomy was performed (RT: n = 7, concomitant chemo radiotherapy (CCRT): n = 14). None of the patients with a combination of intermediate risk factors according to Sedlis (excluding patients >4 cm) underwent adjuvant RT/CCRT. Disease recurrence was observed in 19 patients (10%). Eleven patients died of disease. LVSI influenced progression-free survival (PFS) (HR 3.950, p = 0.0163) and disease-specific survival (DSS) (HR 4.637, p = 0.0497) significantly. However, the combination of LVSI, tumor size and DSI according to Sedlis did not influence overall survival (OS), DSS or PFS.

CONCLUSION

Recurrence rate was low (10%), despite the fact that patients with intermediate risk factors according to Sedlis did not receive postoperative RT/CCRT. LVSI was the sole risk factor influencing PFS and DSS. Combinations of risk factors according to Sedlis did not predict worse outcome.

摘要

介绍

淋巴血管空间侵犯(LVSI)、深层(>1/3)间质浸润(DSI)和大肿瘤尺寸(>4cm)已被确定为 Sedlis 标准中 FIGO 分期 I 期宫颈癌复发的中危预测因素(至少存在上述两个高危因素)。(1,2)在这些患者中主张辅助放疗(RT),但仍存在争议。

方法

所有连续的宫颈癌 FIGO(2009)IB1 期(≤4cm)患者(1997-2017 年)均纳入本回顾性研究。主要目的是分析复发率。次要目的是确定疾病复发和生存的危险因素。

结果

本研究共纳入 182 例患者。中位随访时间为 13 年(8-17 年)。术后,由于存在阳性淋巴结、阳性切片边缘或单纯子宫切除术,21 例患者接受了辅助治疗(RT:n=7,同期放化疗(CCRT):n=14)。没有 Sedlis 标准中存在中危因素的患者(不包括>4cm 的患者)接受了辅助 RT/CCRT。19 例患者(10%)出现疾病复发。11 例患者死于疾病。LVSI 显著影响无进展生存(PFS)(HR 3.950,p=0.0163)和疾病特异性生存(DSS)(HR 4.637,p=0.0497)。然而,Sedlis 标准中的 LVSI、肿瘤大小和 DSI 组合并未影响总生存(OS)、DSS 或 PFS。

结论

尽管 Sedlis 标准中有中危因素的患者未接受术后 RT/CCRT,但复发率仍较低(10%)。LVSI 是唯一影响 PFS 和 DSS 的危险因素。Sedlis 标准中的风险因素组合并不能预测更差的结局。

相似文献

1
Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.FIGO 2009 IB1 期宫颈癌患者行根治性子宫切除术,不辅以辅助放疗,无论 Sedlis 标准是否阳性。
Gynecol Oncol. 2021 Sep;162(3):539-545. doi: 10.1016/j.ygyno.2021.06.026. Epub 2021 Jul 10.
2
Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer.根治性子宫切除术治疗中危早期宫颈癌的辅助治疗作用。
Int J Gynecol Cancer. 2021 Jan;31(1):52-58. doi: 10.1136/ijgc-2020-001974. Epub 2020 Dec 10.
3
The effect of adjuvant radiotherapy on oncological outcomes in patients with early-stage cervical carcinoma with only intermediate-risk factors: a propensity score matching analysis.辅助放疗对仅具有中危因素的早期宫颈癌患者肿瘤学结局的影响:一项倾向评分匹配分析
J Obstet Gynaecol. 2022 Oct;42(7):3204-3211. doi: 10.1080/01443615.2022.2109406. Epub 2022 Aug 12.
4
[Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].32例早期子宫颈神经内分泌癌临床分析
Zhonghua Fu Chan Ke Za Zhi. 2015 Mar;50(3):198-203.
5
Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.国际妇产科联盟(FIGO)IB期无淋巴结转移宫颈癌的预后因素及根治性子宫切除术后辅助放疗的作用
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):286-92. doi: 10.1111/j.1048-891X.2004.014212.x.
6
[Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].[新辅助化疗联合根治性子宫切除术治疗无高危因素的Ⅰb2期和Ⅱa2期宫颈鳞癌的预后分析]
Zhonghua Fu Chan Ke Za Zhi. 2018 Apr 25;53(4):248-256. doi: 10.3760/cma.j.issn.0529-567x.2018.04.008.
7
Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).FIGO IB1期宫颈癌且具有中度危险因素患者根治性子宫切除术后辅助放疗对结局和并发症影响的分析(GOTIC研究)
World J Surg Oncol. 2016 Jun 29;14(1):173. doi: 10.1186/s12957-016-0931-4.
8
Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.手术治疗的 IB1 期-IIB 期宫颈癌伴中危或高危因素患者中,同期放化疗对盆腔放疗的影响:13 年经验。
Int J Gynecol Cancer. 2013 Mar;23(3):567-75. doi: 10.1097/IGC.0b013e31828703fd.
9
The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.2018年国际妇产科联盟(FIGO)IB2期宫颈癌患者行根治性子宫切除术后的最佳肿瘤大小上限。
Int J Gynecol Cancer. 2020 Jul;30(7):975-980. doi: 10.1136/ijgc-2020-001271. Epub 2020 May 28.
10
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?根治性子宫切除术治疗ⅠB1期和ⅠB2期宫颈癌的比较。大小是真正的差异所在吗?
Gynecol Oncol. 2004 Oct;95(1):70-6. doi: 10.1016/j.ygyno.2004.07.027.

引用本文的文献

1
Prognostic value of risk factors in cervical squamous cell carcinoma based on tumour infiltration depth.基于肿瘤浸润深度的宫颈鳞状细胞癌危险因素的预后价值
BMC Cancer. 2025 Sep 2;25(1):1412. doi: 10.1186/s12885-025-14849-8.
2
Development and validation of prognostic prediction models for early-stage cervical cancer patients based on pathological intermediate-risk factors.基于病理中间风险因素的早期宫颈癌患者预后预测模型的开发与验证
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251359461. doi: 10.1177/17588359251359461. eCollection 2025.
3
An MRI radiomics-based model for the prediction of invasion of the lymphovascular space in patients with cervical cancer.
一种基于MRI影像组学的模型用于预测宫颈癌患者的脉管间隙浸润情况。
Front Oncol. 2024 Jul 5;14:1394427. doi: 10.3389/fonc.2024.1394427. eCollection 2024.
4
Role of Adjuvant Radiotherapy in Patients with Cervical Cancer Undergoing Radical Hysterectomy.辅助放疗在接受根治性子宫切除术的宫颈癌患者中的作用。
J Pers Med. 2023 Oct 12;13(10):1486. doi: 10.3390/jpm13101486.
5
Morbidity of adjuvant treatment in early cervical cancer: a retrospective cohort study in a Latin American center.早期宫颈癌辅助治疗的发病率:拉丁美洲某中心的一项回顾性队列研究
Rep Pract Oncol Radiother. 2023 Jun 26;28(2):189-197. doi: 10.5603/RPOR.a2023.0025. eCollection 2023.
6
Prognostic value of lymphovascular space invasion in stage IA to IIB cervical cancer: A meta-analysis.淋巴结脉管间隙浸润对 IA2 期至 IIB 期宫颈癌的预后价值:一项荟萃分析。
Medicine (Baltimore). 2023 Apr 14;102(15):e33547. doi: 10.1097/MD.0000000000033547.
7
Prognostic analysis of pT1-T2aN0M0 cervical adenocarcinoma based on random survival forest analysis and the generation of a predictive nomogram.基于随机生存森林分析及预测列线图生成的pT1-T2aN0M0宫颈腺癌预后分析
Front Oncol. 2022 Nov 24;12:1049097. doi: 10.3389/fonc.2022.1049097. eCollection 2022.
8
Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.子宫颈癌患者根治性子宫切除术后存在中危因素的风险评估:日本妇科肿瘤学组的多中心回顾性分析
Int J Clin Oncol. 2022 Sep;27(9):1507-1515. doi: 10.1007/s10147-022-02198-6. Epub 2022 Jun 14.
9
The diagnostic value of core needle biopsy in cervical cancer: A retrospective analysis.宫颈癌症中核心针活检的诊断价值:一项回顾性分析。
PLoS One. 2022 Jan 5;17(1):e0262257. doi: 10.1371/journal.pone.0262257. eCollection 2022.